CD33 and acute myeloid leukemia: A recent study has confirmed efficacy and safety of GO addition to standard 3 + 7 chemotherapy also in FLT3 mutated AML; furthermore, GO combination with midostaurin‐based induction regimens in FLT3 mutated CD33+ AML has been proposed with clinical benefits and tolerability with slightly prolonged neutropenia.11, 18, 19